Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

NCCN Task Force Report: mTOR inhibition in solid tumors.

Publication ,  Journal Article
Figlin, RA; Brown, E; Armstrong, AJ; Akerley, W; Benson, AB; Burstein, HJ; Ettinger, DS; Febbo, PG; Fury, MG; Hudes, GR; Kies, MS; Kwak, EL ...
Published in: J Natl Compr Canc Netw
September 2008

The mammalian target of rapamycin (mTOR) protein complex functions as an integration center for various intracellular signaling pathways involving cell cycle progression, proliferation, and angiogenesis. These pathways are frequently dysregulated in cancer, and therefore mTOR inhibition is a potentially important antitumor target. Commercially available mTOR inhibitors include rapamycin (i.e., sirolimus) and temsirolimus. Other agents under investigation include everolimus and deforolimus. mTOR inhibition has been studied in various solid tumors, including breast, gynecologic, gastrointestinal, prostate, lung, and head and neck cancers. Studies have focused on mTOR inhibition as a monotherapy or in combination with other drugs based on the principle that inhibiting as many targets as possible reduces the emergence of drug resistance. Temsirolimus is currently the only mTOR inhibitor that is specifically labeled for treatment of solid tumors. However, preclinical studies and early-phase trials are rapidly evolving. Additionally, research is further defining the complicated mTOR pathways and how they may be disordered in specific malignancies. To address these issues, NCCN convened a task force to review the underlying physiology of mTOR and related cellular pathways, and to review the current status of research of mTOR inhibition in solid tumors.

Duke Scholars

Published In

J Natl Compr Canc Netw

ISSN

1540-1405

Publication Date

September 2008

Volume

6 Suppl 5

Start / End Page

S1 / 20

Location

United States

Related Subject Headings

  • TOR Serine-Threonine Kinases
  • Sirolimus
  • Signal Transduction
  • Protein Kinases
  • Protein Kinase Inhibitors
  • Practice Guidelines as Topic
  • Oncology & Carcinogenesis
  • Neoplasms
  • Humans
  • Everolimus
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Figlin, R. A., Brown, E., Armstrong, A. J., Akerley, W., Benson, A. B., Burstein, H. J., … Yen, Y. (2008). NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw, 6 Suppl 5, S1-20.
Figlin, Robert A., Elizabeth Brown, Andrew J. Armstrong, Wallace Akerley, Al B. Benson, Harold J. Burstein, David S. Ettinger, et al. “NCCN Task Force Report: mTOR inhibition in solid tumors.J Natl Compr Canc Netw 6 Suppl 5 (September 2008): S1-20.
Figlin RA, Brown E, Armstrong AJ, Akerley W, Benson AB, Burstein HJ, et al. NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw. 2008 Sep;6 Suppl 5:S1-20.
Figlin, Robert A., et al. “NCCN Task Force Report: mTOR inhibition in solid tumors.J Natl Compr Canc Netw, vol. 6 Suppl 5, Sept. 2008, pp. S1-20.
Figlin RA, Brown E, Armstrong AJ, Akerley W, Benson AB, Burstein HJ, Ettinger DS, Febbo PG, Fury MG, Hudes GR, Kies MS, Kwak EL, Morgan RJ, Mortimer J, Reckamp K, Venook AP, Worden F, Yen Y. NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw. 2008 Sep;6 Suppl 5:S1-20.

Published In

J Natl Compr Canc Netw

ISSN

1540-1405

Publication Date

September 2008

Volume

6 Suppl 5

Start / End Page

S1 / 20

Location

United States

Related Subject Headings

  • TOR Serine-Threonine Kinases
  • Sirolimus
  • Signal Transduction
  • Protein Kinases
  • Protein Kinase Inhibitors
  • Practice Guidelines as Topic
  • Oncology & Carcinogenesis
  • Neoplasms
  • Humans
  • Everolimus